Modulation of transgene expression in mesothelial cells by activation of an inducible promoter

Nephrology Dialysis Transplantation

Volumn 13, Issue 6, 1998, Pages 1420-1429

  Hoff, Catherine M ^a   Cusick, Jennifer L ^b   Masse, Elizabeth M ^b   Jackman, Robert W ^b   Nagy, Janice A ^b   Shockley, Ty R ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dexamethasone; Ex vivo gene transfer; Gene therapy; Heavy metal ions; Human growth hormone; Inducible promoter; Intraperitoneal; Mesothelial cells; mMT 1; Peritoneal cavity; Peritoneal dialysis; Peritoneal mesothelium; Systemic delivery

Indexed keywords

DEXAMETHASONE; HEAVY METAL; HUMAN GROWTH HORMONE; METALLOTHIONEIN; ZINC ION; METALLOTHIONEIN I; ZINC;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; FEMALE; GENE EXPRESSION; GENE TRANSFER; HORMONE SYNTHESIS; MESOTHELIUM CELL; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL; PROMOTER REGION; RAT; TRANSGENE; CONFERENCE PAPER; CONTROLLED STUDY; EX VIVO GENE TRANSFER; IN VITRO STUDY; SOUTHERN BLOTTING;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BASE SEQUENCE; CLONE CELLS; DEXAMETHASONE; DNA PRIMERS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GLUCOCORTICOIDS; HUMAN GROWTH HORMONE; HUMANS; MICE; PERITONEAL DIALYSIS; PERITONEUM; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RATS; ZINC;

EID: 0031800507     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.6.1420     Document Type: Article

References (45)

1. Gotloib L, Shostak A. The functional anatomy of the peritoneal membrane as a dialysing membrane. In: Twardowski ZJ, Nolph KD, ed. Peritoneal Dialysis. Churchill Livingstone: New York, 1990; 1-27
2. Holmes CJ. Biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1993; 13: 88-94
3. Hjelle JT, Miller-Hjelle MA, Dobbie JW. The biology of the mesothelium during peritoneal dialysis. Perit Dial Int 1995; 15: SI3-S23
4. Krediet RT, Ho-Dak-Pannekeet MM, Struijk DG. Preservation of peritoneal membrane function. Kidney Int 1996; 50 [Suppl 56]: S62-S68
5. Verger C. Peritoneal ultrastructure. In: Nolph KD, ed. Peritoneal Dialysis. Martinus Nijhoff, Boston, 1985; 95-113
6. Yang AH, Chen JY, Lin YP, Huang TP, Wu CW. Peritoneal dialysis solution induces apoptosis of mesothelial cells. Kidney Int 1997; 51: 1280-1288
7. Rubin J, Guillermo A, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. 1991; 18: 97-102
8. Vanholder R, Lameire N, Waterloos MA et al. Disturbed host defense in peritoneal cavity during CAPD: characterization of responsible factors in dwell fluid. Kidney Int 1996; 50: 643-652
9. Topley N, Williams JD. Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. Kidney Int 1994; 46 [Suppl 48]: S71-S78
10. Holmes CJ. Peritoneal host defense mechanisms in peritoneal dialysis. Kidney Int 1994; 46 [Suppl 48]: S58-S70
11. Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72: 171-176
12. Nagy JA, Shockley TR, Masse EM, Harvey VS, Jackman RW. Mesothelial cell-mediated gene therapy: feasibility of an ex vivo strategy. Gene Ther 1995; 2: 393-401
13. Nagy JA, Shockley TR, Masse EM, Harvey VS, Hoff CM, Jackman RW. Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface. Gene Ther 1995; 2: 402-410
14. Shockley TR, Nagy JA, Jackman RW. Expression of thrombomodulin by ex vivo mesothelial cell-mediated gene therapy demonstrates a novel strategy to enhance the function of the peritoneal mesothelium in vivo. (abstract). J Am Soc Nephrol 1996; 7: 1434
15. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for gene therapy. Hum Gene Ther 1997; 8: 803-815
16. Searle PF, Stuart GW, Palmiter RD. Building a metal-responsive promoter with synthetic regulatory elements. Mol Cell Biol 1985; 5: 1480-1489
17. Selden RF, Burke-Howie K, Rowe ME, Goodman HM, Moore DD. Human growth hormone as a reporter gene in regulation studies employing transient gene expression. Mol Cell Biol 1986; 6: 3173-3179
18. Pack I, Axel R. Glucocorticoids enhance stability of human growth hormone mRNA. Mol Cell Biol 1987; 7: 1496-1507
19. Diamond DJ, Goodman HM. Regulation of growth hormone messenger RNA synthesis by dexamethasone and triiodothyronine: transcriptional rate and mRNA stability changes in pituitary tumor cells. J Mol Biol 1985; 181: 41-62
20. Selden RF, Skoskiewicz MJ, Burke-Howie K, Russell PS, Goodman HM. Implantation of genetically engineered fibroblasts into mice: implications for gene therapy. Science 1987; 236: 714-718
21. Brigham KL, Meyrick B, Christian B et al. Expression of human growth hormone fusion genes in cultured lung endothelial cells and in the lungs of mice. Am J Respir Cell Mol Biol 1993; 8: 209-213
22. Selden RF, Yun JS, Moore DD et al. Glucocorticoid regulation of human growth hormone expression in transgenic mice and transiently transfected cells. J Endocrinol 1989; 122: 49-60
23. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2 edn. Cold Spring Harbor Laboratory Press, Plainview, NY, 1989
24. Renvall SY. Peritoneal metabolism and intraabdominal adhesion formation during experimental peritonitis. Acta Chir Scan Suppl 1980; 503: 1-48
25. Bertalanffy FD, Lau C. Cell Renewal. Intern Rev Cytol 1962; 13: 357-366
26. Palmiter RD. Regulation of metallothionein genes by heavy metals appears to be mediated by a zinc-sensitive inhibitor that interacts with a constitutively active transcription factor, MTF-1. Proc. Natl. Acad. Sci USA 1994; 91: 1219-1223
27. Gossen M, Bujard H. Tight control opf gene expression in mammalian cells by tetracycline-responsive promoters. PNAS 1992; 89: 5547-5551
28. Wang Y, Xu J, Pierson T, O'Malley BW, Tsai SY. Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator. Gene Ther 1997; 4: 432-441
29. Bos HJ, Struijk DG, Tuk CW et al. Peritoneal dialysis induces a local sterile inflammatory state and the mesothelial cells in the effluent are related to the bacterial peritonitis incidence. Nephron 1991; 59: 508-509
30. Dobbie JW. Ultrastructure and pathology of the peritoneum in peritoneal dialysis. In: Gokal R, Nolph KD, ed. The Textbook of Peritoneal Dialysis. Kluwer Academic Publishers: Dordrecht. 1994; 17-44
31. Gotloib L, Shostack A, Bar-Sella P, Cohen R. Continuous mesothelial injury and regeneration during long term peritoneal dialysis. Perit Dial Bull 1987; 7: 148-155
32. Heimbürger O, Waniewski J, Wernynski A, Tranaeus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 495-506
33. Henderson I, Gokal R. Loss of ultrafiltration in CAPD. In: Gokal R, ed. Continuous Ambulatory Peritoneal Dialysis. Churchill Livingstone, Edinburgh, 1986; 218-227
34. Rippe B. Pathophysiological description of the ultrastructural changes of the peritoneal membrane during long-term continuous peritoneal dialysis. Blood Purif 1994; 12: 211-220
35. Zemel D, Krediet RT. Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Blood Purif 1996; 14: 198-216
36. Sitter T, Spannagl M, Schiffl H, Held E, van Hinsbergh VWM, Kooistra T. Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells. Nephrol Dial Transplant 1995; 10: 677-683
37. Wadhwa NK, Lin J-J, Parton L, Bereket G, Cabralda T, Suh H. Plasminogen activator inhibitor-1 and peritoneal transport in peritoneal dialysis patients. Adv Perit Dial 1996; 12: 33-38
38. Topley N, MacKenzie RK, Williams JD. Macrophages and mesothelial cells in bacterial peritonitis. Immunobiology 1996; 195: 563-573
39. Hassan MQ, S.A.Hussain, Zaki MA, Alsharif NZ, Slobs SJ. Protective effects of antioxidants against uraemia-induced lipid peroxidation and glutathione depletion in humans. Pharmacol Toxicol 1995; 77: 407-411
40. Andreoli SP, Mallett C, Williams K, McAteer JA, Rothlein R, Doerschuk CM. Mechanisms of polymorphonuclear leukocyte mediated peritoneal mesothelial cell injury. Kidney Int 1994; 46: 1100-1109
41. Nakayama M, Kawaguchi Y, Yamada K el al. Immunohistochemical detection of advanced glycation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182-186
42. Friedlander MA, Wu YC, Elgawish A, Monnier VM. Early and advanced glycosylation end products. J Clin Invest 1996; 97: 728-735
43. Dawnay A. Advanced glycation end products in peritoneal dialysis. Peril Dial Int 1996; 16 [Suppl 1]: S50-S53
44. Varley AW, Coulthard MG, Meidell RS, Gerard RD, Munford RS. Inflammation-induced recombinant protein expression in vivo using promoters from acute-phase protein genes. PNAS 1995; 92: 5346-5350
45. Hoff CM, Nagy JA, Jackman RW, Shockley TR. Regulation of transgene expression in mesothelial cells by an inducible promoter. J Am Soc Nephrol 1995; 6: 793